2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2017
Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature.
Gressel G, Buza N, Pal L. Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature. European Journal Of Gynaecological Oncology 2017, 38: 214-220. PMID: 29953783.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansHyperandrogenismHysterectomyMiddle AgedNeoadjuvant TherapyNeoplasm GradingOvarian NeoplasmsOvariectomyPostmenopauseRetrospective StudiesSalpingectomySertoli-Leydig Cell TumorConceptsSertoli-Leydig cell tumorOvarian Sertoli-Leydig cell tumorPresent patient populationDisease-free survivalSingle institution experienceTertiary care institutionTime of diagnosisOnset of menopauseRisk of recurrenceSeries of casesAdjuvant chemotherapyMedian followPostmenopausal bleedingPostmenopausal patientsMedian ageMedian intervalClinical presentationDefinitive managementPathological findingsRetrospective reviewInstitution experiencePatient populationTreatment modalitiesCell tumorsTumor grade